Extended Data Fig. 4. iCAR-TCTL suppressed tumor progression but did not reach pCAR-TCTL.
a–d. Treatment schedule of the ovarian cancer peritoneal dissemination xenograft model (a) NSG mice were injected intraperitoneally with 5 × 105 KOC7c cells expressing luciferase. From the third day after the ovarian cancer inoculation, 5 × 106 iCAR-TCTL, iCAR-TILC, or pCAR-TCTL were injected intraperitoneally twice a week for 2 weeks (n = 6 for each group). In vivo bioluminescence imaging of luciferase-labeled KOC7c in NSG mice treated with iCAR-TILC, iCAR-TCTL, or pCAR-TCTL(b). Change in the total body flux as the total tumor volume (lower left panel, mean ± SEM) (c) and survival (lower right panel) were evaluated at the indicated time points after the injection (d). One-way ANOVA with Tukey’s multiple comparisons test and log-rank test with Bonferroni multiple comparisons test.